Explore the words cloud of the ZIKAVAX project. It provides you a very rough idea of what is the project "ZIKAVAX" about.
The following table provides information about the project.
EUROPEAN VACCINE INITIATIVE EWIV
|Coordinator Country||Germany [DE]|
|Total cost||4˙918˙137 €|
|EC max contribution||4˙918˙137 € (100%)|
1. H2020-EU.3.1.2. (Preventing disease)
|Duration (year-month-day)||from 2016-10-01 to 2020-09-30|
Take a look of project's partnership.
|1||EUROPEAN VACCINE INITIATIVE EWIV||DE (HEIDELBERG)||coordinator||673˙968.00|
|2||THEMIS BIOSCIENCE GMBH||AT (WIEN)||participant||3˙192˙862.00|
|3||INSTITUT PASTEUR||FR (PARIS CEDEX 15)||participant||562˙290.00|
|4||COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES||FR (PARIS 15)||participant||489˙016.00|
Zika virus is an emerging mosquito-borne flavivirus. Although already isolated in 1947, to date there are no specific treatments nor any vaccines available against Zika virus disease, making it a truly neglected infectious disease. The recent rapid spread of the Zika virus in previously unaffected regions has provided strong epidemiological evidence that infection with this virus might be associated with neurological complications in adults and with an increase in severe congenital brain malformations of new-borns. Consequently, the World Health Organization has declared the recent outbreak of the Zika virus a public health emergency. The ZIKAVAX proposal has the objective to address this urgent public health issue by promoting the rapid development of a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX will use a delivery platform technology based on a measles vaccine vector with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. The manufacturing process for these measles vector-based vaccines has been developed to give high yield and purity using standard equipment. In ZIKAVAX, following antigen selection and expression, immunisation studies will be conducted with the Zika vaccine candidate in mice and in a challenge model in non-human primates that will developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate in adult volunteers in a phase Ia clinical trial. ZIKAVAX is driven by a strongly committed and effective consortium of four leading European organisations highly experienced in vaccine research and development. Its partners include the European Vaccine Initiative, Institut Pasteur, Themis Bioscience GmbH and the Institute of Emerging Diseases and Innovative Therapies from the Commissariat à l’Energie Atomique.
|Launch of the website||Websites, patent fillings, videos etc.||2019-05-30 15:16:10|
Take a look to the deliverables list in detail: detailed list of ZIKAVAX deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZIKAVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ZIKAVAX" are provided by the European Opendata Portal: CORDIS opendata.